The nuclear medicine group of Siemens Medical Systems in Hoffman Estates, IL, is giving a higher profile to its gamma camera remanufacturing capability. The company last month launched its Siemens Remanufactured Product (SRP) line, which it plans to
The nuclear medicine group of Siemens Medical Systems in Hoffman Estates, IL, is giving a higher profile to its gamma camera remanufacturing capability. The company last month launched its Siemens Remanufactured Product (SRP) line, which it plans to position as a viable alternative to new gamma cameras.
SRP cameras undergo a seven-step remanufacturing process, in which the systems are disassembled and rebuilt, with components repaired or replaced if necessary. The cameras are also refinished and include a one-year warranty, with a three-year warranty for crystals. Siemens claims that in some cases the systems emerge from the process better than when they were sold because they are brought up to current specifications, with state-of-the-art detectors, electronics, and other components.
In other Siemens nuclear medicine news, the company has released a new version of its ECAT ART positron emission tomography camera. Unveiled at the European Association of Nuclear Medicine meeting, the new ECAT ART features iterative reconstruction algorithms for better image quality and a single-photon scanning method that enables higher throughput for whole-body attenuation-corrected studies. Siemens first introduced ECAT ART at the 1994 Society of Nuclear Medicine meeting, and the camera carries a list price of $1.2 million (SCAN 6/15/94).
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.